PMID- 27517350
OWN - NLM
STAT- MEDLINE
DCOM- 20170901
LR  - 20181202
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 62
DP  - 2016 Sep
TI  - Randomized double-blind comparison of cognitive and EEG effects of lacosamide and 
      carbamazepine.
PG  - 267-75
LID - S1525-5050(16)30239-6 [pii]
LID - 10.1016/j.yebeh.2016.07.007 [doi]
AB  - Differential effectiveness of antiepileptic drugs (AEDs) is more commonly 
      determined by tolerability than efficacy. Cognitive effects of AEDs can adversely 
      affect tolerability and quality of life. This study evaluated cognitive and EEG 
      effects of lacosamide (LCM) compared with carbamazepine immediate-release 
      (CBZ-IR). A randomized, double-blind, double-dummy, two-period crossover, 
      fixed-dose study in healthy subjects compared neuropsychological and EEG effects 
      of LCM (150mg, b.i.d.) and CBZ-IR (200mg, t.i.d.). Testing was conducted at 
      screening, predrug baseline, the end of each treatment period (3-week titration; 
      3-week maintenance), and the end of each washout period (4weeks after treatment). 
      A composite Z-score was derived for the primary outcome variable (computerized 
      cognitive tests and traditional neuropsychological measures) and separately for 
      the EEG measures. Other variables included individual computer, 
      neuropsychological, and EEG scores and adverse events (AEs). Subjects included 60 
      healthy adults (57% female; mean age: 34.4years [SD: 10.5]); 44 completed both 
      treatments; 41 were per protocol subjects. Carbamazepine immediate-release had 
      worse scores compared with LCM for the primary composite neuropsychological 
      outcome (mean difference=0.33 [SD: 1.36], p=0.011) and for the composite EEG 
      score (mean difference=0.92 [SD: 1.77], p=0.003). Secondary analyses across the 
      individual variables revealed that CBZ-IR was statistically worse than LCM on 36% 
      (4/11) of the neuropsychological tests (computerized and noncomputerized) and 0% 
      of the four EEG measures; none favored CBZ-IR. Drug-related AEs occurred more 
      with CBZ-IR (49%) than LCM (22%). Lacosamide had fewer untoward 
      neuropsychological and EEG effects and fewer AEs and AE-related discontinuations 
      than CBZ-IR in healthy subjects. Lacosamide exhibits a favorable cognitive 
      profile.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Meador, Kimford J
AU  - Meador KJ
AD  - Department of Neurology and Neurological Sciences, Stanford University, Stanford, 
      CA, USA. Electronic address: kmeador@stanford.edu.
FAU - Loring, David W
AU  - Loring DW
AD  - Department of Neurology, Emory University, Atlanta, GA, USA; Department of 
      Pediatrics, Emory University, Atlanta, GA, USA. Electronic address: 
      dloring@emory.edu.
FAU - Boyd, Alan
AU  - Boyd A
AD  - CNS Vital Signs, Morrisville, NC, USA. Electronic address: aboyd@cnsvs.com.
FAU - Echauz, Javier
AU  - Echauz J
AD  - JE Research, Inc., Alpharetta, GA, USA. Electronic address: echauz@ieee.org.
FAU - LaRoche, Suzette
AU  - LaRoche S
AD  - Department of Neurology, Emory University, Atlanta, GA, USA. Electronic address: 
      Suzette.LaRoche@msj.org.
FAU - Velez-Ruiz, Naymee
AU  - Velez-Ruiz N
AD  - Department of Neurology, Emory University, Atlanta, GA, USA. Electronic address: 
      nxv146@med.miami.edu.
FAU - Korb, Pearce
AU  - Korb P
AD  - Department of Neurology, University of Colorado, Denver, CO, USA. Electronic 
      address: pearce.korb@ucdenver.edu.
FAU - Byrnes, William
AU  - Byrnes W
AD  - UCB Pharma, Raleigh, NC, USA. Electronic address: Bill.Byrnes@ucb.com.
FAU - Dilley, Deanne
AU  - Dilley D
AD  - UCB Pharma, Raleigh, NC, USA. Electronic address: Deanne.Dilley@ucb.com.
FAU - Borghs, Simon
AU  - Borghs S
AD  - UCB Pharma, Slough, UK. Electronic address: Simon.Borghs@ucb.com.
FAU - De Backer, Marc
AU  - De Backer M
AD  - UCB Pharma, Brussels, Belgium. Electronic address: Marc.DeBacker@ucb.com.
FAU - Story, Tyler
AU  - Story T
AD  - UCB Pharma, Atlanta, GA, USA. Electronic address: TylerJStory@gmail.com.
FAU - Dedeken, Peter
AU  - Dedeken P
AD  - UCB Pharma, Brussels, Belgium. Electronic address: Peter.Dedeken@ucb.com.
FAU - Webster, Elizabeth
AU  - Webster E
AD  - UCB Pharma, Raleigh, NC, USA. Electronic address: Elizabeth.Webster@ucb.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT01530022
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160810
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
RN  - 0 (Acetamides)
RN  - 0 (Anticonvulsants)
RN  - 33CM23913M (Carbamazepine)
RN  - 563KS2PQY5 (Lacosamide)
SB  - IM
MH  - Acetamides/*pharmacology
MH  - Adolescent
MH  - Adult
MH  - Anticonvulsants/*pharmacology
MH  - Brain/*drug effects
MH  - Carbamazepine/*pharmacology
MH  - Cognition/*drug effects
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Electroencephalography
MH  - Female
MH  - Humans
MH  - Lacosamide
MH  - Male
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Young Adult
OTO - NOTNLM
OT  - Carbamazepine
OT  - Cognition
OT  - EEG
OT  - Lacosamide
OT  - Neuropsychology
EDAT- 2016/08/16 06:00
MHDA- 2017/09/02 06:00
CRDT- 2016/08/13 06:00
PHST- 2016/05/19 00:00 [received]
PHST- 2016/07/01 00:00 [revised]
PHST- 2016/07/02 00:00 [accepted]
PHST- 2016/08/13 06:00 [entrez]
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2017/09/02 06:00 [medline]
AID - S1525-5050(16)30239-6 [pii]
AID - 10.1016/j.yebeh.2016.07.007 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2016 Sep;62:267-75. doi: 10.1016/j.yebeh.2016.07.007. Epub 2016 
      Aug 10.